Attrition sorts the classes. Weekly Biotech Signal Review · Completed reporting week: October 24–October 30, 2026 · Published October 31, 2026 Report at a glance: Geron stopped a 327-patient Phase 3 on survival futility,…
A cure endpoint, a rebound, and milestone-heavy deals. Weekly Biotech Signal Review · Completed reporting week: October 17–October 23, 2026 · Published October 24, 2026 Report at a glance: The FDA approved the first…
Randomized evidence, fragile risk appetite. Weekly Biotech Signal Review · Completed reporting week: October 10–October 16, 2026 · Published October 17, 2026 Report at a glance: A randomized NEJM trial favored a chemotherapy-free regimen…
Evidence funds the next proof point. Weekly Biotech Signal Review · Completed reporting week: October 3–October 9, 2026 · Published October 10, 2026 Report at a glance: Vaxcyte turned a pivotal pneumococcal readout into…
Evidence before optionality — a first-line label expansion backed by an 80% risk reduction led the week, large pharma wrote roughly $2.3 billion of upfront checks for early-stage modalities, and two programs that could…
The week’s most important signal was not a new platform claim but five-year, maintenance-free disease control after a single cilta-cel infusion in early-line relapsed or refractory multiple myeloma — and the broader pattern held…
Two rare-disease approvals landed ahead of their own clocks, the FDA launched a pilot explicitly designed to compress first-in-human timelines, and a $350 million IPO priced and opened without a pop — a week…
Four approvals, a first-ever in-vivo CRISPR filing accepted with Priority Review, two high-profile pivotal misses, and roughly $1.6 billion of confirmed private financing — a week where mechanism mattered less than manufacturing, endpoint choice…
Six approvals, a pivotal cardiovascular-outcomes miss, two paused autoimmune cell-therapy programs, and roughly $6.9 billion of headline dealmaking — this week’s signals only counted once verified against a primary source. Weekly Biotech Signal Review…
Biotech had an approval week that tested whether comparative human evidence still beats platform storytelling. Broad active-state RAS inhibition crossed from thesis to approved medicine when the FDA cleared Rasonque after a 500-patient randomized…
